Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial.
Yukiyasu OkamuraNarikazu BokuPaula GhanehWilliam GreenhalfSatoru YasukawaHiroto NarimatsuAkira FukutomiMasaru KonishiSoichiro MorinagaHirochika ToyamaAtsuyuki MaedaYasuhiro ShimizuShoji NakamoriNaohiro SataKeisuke YamakitaAmane TakahashiWataru TakayamaRyuzo YamaguchiMoriaki TomikawaAkio YanagisawaJohn P NeoptolemosKatsuhiko UesakaPublished in: Cancer reports (Hoboken, N.J.) (2021)
The present study suggests that the two antibodies for evaluating hENT1 expression are equivalent depending on the cut-off point and suggests that S-1 is the first choice of adjuvant chemotherapy for pancreatic cancer with low hENT1 expression, whereas either S-1 or GEM can be introduced for the pancreatic cancer with high hENT1 expression, no matter which antibody is used.